Nigella sativa oil affects glucose metabolism and lipid concentrations in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial

被引:70
|
作者
Heshmati, Javad [1 ]
Namazi, Nazli [2 ]
Memarzadeh, Mohammad-Reza [3 ]
Taghizadeh, Mohsen [3 ]
Kolandooz, Fariba [4 ]
机构
[1] Kermanshah Univ Med Sci, Hlth Care Ctr, Kermanshah, Iran
[2] Tabriz Univ Med Sci, Fac Nutr, Nutr Res Ctr, Tabriz, Iran
[3] Barij Essence Pharmaceut Co, Ctr Res & Dev, Kashan, Iran
[4] Univ Alberta, Dept Med, Fac Med & Dent, Aboriginal & Global Hlth Res Grp, Edmonton, AB, Canada
关键词
Nigella sativa; Blood glucose; Dyslipidemias; Diabetes mellitus; Type; 2; MEDICINAL-PLANTS; URTICA-DIOICA; SEED EXTRACT; THYMOQUINONE; PEROXIDATION; PROFILE;
D O I
10.1016/j.foodres.2015.01.030
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
The aim of the present study was to determine the effects of Nigella sativa (NS) oil on glucose metabolism and lipid concentrations in patients with type 2 diabetes (T2DM). In this double-blind randomized controlled clinical trial, 72 volunteer subjects at Endocrinology Clinics of Kermanshah were recruited. Participants were patients aged 30-60 years old with T2DM. They were randomly divided into intervention (n = 36) and placebo groups (n = 36) and received 3 g/day (one three times a day) NS oil or sunflower soft gel capsules for 12 weeks. At baseline and at the end of the trial, anthropometric indices, dietary intake and biochemical parameters were measured. Sixty-seven patients completed the trial (intervention n = 34, placebo n = 33). Since the data analysis was based on intention-to-treat approach, all 72 subjects (36 in each group) were included for data analysis. Two groups were similar in the baseline characteristics. After the intervention, weight and body mass index decreased in the intervention group compared to the baseline, but it was not significant between the two groups. Dietary intake in both groups changed compared to baseline. Comparison of the two groups indicated that fasting blood sugar, glycated hemoglobin, triglyceride and low density lipoprotein-cholesterol changed significantly in intervention group compared to the placebo group (p < 0.05, adjusted for confounder factors). Insulin level and insulin resistance decreased and high density lipoprotein-cholesterol increased in the intervention group, but after adjusting for confounder factors, they were not significant. Supplementation with NS oil can improve glycemic status and lipid profile in patients with T2DM. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:87 / 93
页数:7
相关论文
共 50 条
  • [31] Effects Of Saffron Supplementation On Inflammation And Metabolic Responses In Type 2 Diabetic Patients: A Randomized, Double-Blind, Placebo-Controlled Trial
    Ebrahimi, Fatemeh
    Sahebkar, Amirhossein
    Aryaeian, Naheed
    Pahlavani, Naseh
    Fallah, Soudabeh
    Moradi, Nariman
    Abbasi, Davoud
    Hosseini, Agha Fatemeh
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2019, 12 : 2107 - 2115
  • [32] Effect of Brazilian green propolis in patients with type 2 diabetes: A double-blind randomized placebo-controlled study
    Fukuda, Takuya
    Fukui, Michiaki
    Tanaka, Muhei
    Senmaru, Takafumi
    Iwase, Hiroya
    Yamazaki, Masahiro
    Aoi, Wataru
    Inui, Toshio
    Nakamura, Naoto
    Marunaka, Yoshinori
    BIOMEDICAL REPORTS, 2015, 3 (03) : 355 - 360
  • [33] The effects of citrulline supplementation on meta-inflammation and insulin sensitivity in type 2 diabetes: a randomized, double-blind, placebo-controlled trial
    Abbaszadeh, Fatemeh
    Azizi, Samaneh
    Mobasseri, Majid
    Ebrahimi-Mameghani, Mehrangiz
    DIABETOLOGY & METABOLIC SYNDROME, 2021, 13 (01)
  • [34] The effects of wheat germ supplementation on metabolic profile in patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled trial
    Mohammadi, Hamed
    Karimifar, Mozhgan
    Heidari, Zahra
    Zare, Maryam
    Amani, Reza
    PHYTOTHERAPY RESEARCH, 2020, 34 (04) : 879 - 885
  • [35] Nigella sativa and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: Results from a randomized, double-blind, placebo-controlled, clinical trial
    Darand, Mina
    Darabi, Zahra
    Yari, Zahra
    Saadati, Saeedeh
    Hedayati, Mehdi
    Khoncheh, Ahmad
    Hosseini-Ahangar, Behnam
    Alavian, Seyed Moayyed
    Hekmatdoost, Azita
    COMPLEMENTARY THERAPIES IN MEDICINE, 2019, 44 : 204 - 209
  • [36] Standardized Nigella sativa seed oil ameliorates hepatic steatosis, aminotransferase and lipid levels in non-alcoholic fatty liver disease: A randomized, double-blind and placebo-controlled clinical trial
    Khonche, Ahmad
    Huseini, Hasan Fallah
    Gholamian, Mandi
    Mohtashami, Reza
    Nabati, Farzaneh
    Kianbakht, Saeed
    JOURNAL OF ETHNOPHARMACOLOGY, 2019, 234 : 106 - 111
  • [37] The impact of L-citrulline supplementation on glucose homeostasis, lipid profile, and some inflammatory factors in overweight and obese patients with type 2 diabetes: A double-blind randomized placebo-controlled trial
    Azizi, Samaneh
    Mahdavi, Reza
    Mobasseri, Majid
    Aliasgharzadeh, Soghra
    Abbaszadeh, Fatemeh
    Ebrahimi-Mameghani, Mehrangiz
    PHYTOTHERAPY RESEARCH, 2021, 35 (06) : 3157 - 3166
  • [38] Zinc supplementation in prediabetes: A randomized double-blind placebo-controlled clinical trial
    Ranasinghe, Priyanga
    Wathurapatha, Wasundara S.
    Galappatthy, Priyadarshani
    Katulanda, Prasad
    Jayawardena, Ranil
    Constantine, Godwin R.
    JOURNAL OF DIABETES, 2018, 10 (05) : 386 - 397
  • [39] A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with Schizophrenia
    Henderson, D. C.
    Fan, X.
    Sharma, B.
    Copeland, P. M.
    Borba, C. P.
    Boxill, R.
    Freudenreich, O.
    Cather, C.
    Evins, A. Eden
    Goff, D. C.
    ACTA PSYCHIATRICA SCANDINAVICA, 2009, 119 (06) : 457 - 465
  • [40] Improvements to postprandial glucose control in subjects with type 2 diabetes: a multicenter, double blind, randomized placebo-controlled trial of a novel probiotic formulation
    Perraudeau, Fanny
    McMurdie, Paul
    Bullard, James
    Cheng, Andrew
    Cutcliffe, Colleen
    Deo, Achal
    Eid, John
    Gines, Jessica
    Iyer, Mohan
    Justice, Nicholas
    Loo, Wesley T.
    Nemchek, Madeleine
    Schicklberger, Marcus
    Souza, Michael
    Stoneburner, Brendon
    Tyagi, Surabhi
    Kolterman, Orville
    BMJ OPEN DIABETES RESEARCH & CARE, 2020, 8 (01)